Preston Klassen, President & Head of R & D at Regulus Therapeutics Inc. (RGLS), sold 31,445 shares at $1.26 ($40K) on 2025-01-13, disclosed to the SEC on 2025-01-15.
Scheduled sale ($40k) by President & Head of R & D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MTCR | SELL | 2022-04-20 | $22K | — | Filing → |
| MTCR | BUY | 2021-05-20 | $150K | — | Filing → |
| ARNA | SELL | 2019-01-08 | $816K | — | Filing → |